Effects of sitagliptin beyond glycemic control: focus on quality of life
Authors:
- Yoshiko SakamotoYSYoshiko Sakamoto
- Jun-Ichi OyamaJOJun-Ichi Oyama
- Hideo IkedaHIHideo Ikeda
- Shigeki GondoSGShigeki Gondo
- Taketo IwamotoTITaketo Iwamoto
- Yasufumi UchidaYUYasufumi Uchida
- Kazuhisa KodamaKKKazuhisa Kodama
- Atsushi HiwatashiAHAtsushi Hiwatashi
- Mitsuhiro ShimomuraMSMitsuhiro Shimomura
- Isao TaguchiITIsao Taguchi
- Teruo InoueTITeruo Inoue
Open Access
- 21 February 2013
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 35
Abstract
Background: Recently, incretin hormones, including glucagon-like peptide-1 (GLP-1) analogue and dipeptidyl peptidase-4 (DPP-4) inhibitor, have been found to regulate glucose metabolism. The aim of this study was to elucidate the efficacy and safety of the clinical usage of DPP-4 inhibitors in Japan. Methods: This study was designed as a prospective, open-label, multi-center trial. Patients with diabetes mellitus type 2 (T2DM) with poor glycemic profiles (HbA1c ≥ 6.2%) in spite of receiving a medical diet, therapeutic exercise, and/or medications were eligible for this study. The participants received 50 to 100 mg of the DPP-4 inhibitor sitagliptin once daily for 12 months. Results: One hundred and eighty-eight subjects were enrolled. After 12 months of sitagliptin treatment, HbA1c levels decreased (7.65% ± 1.32% to 7.05% ± 1.10%, p < 0.001) as well as fasting plasma glucose (FPG) (145 ± 52 mg/dl to 129 ± 43 mg/dl, p = 0.005). The rate of glycemic control achieved (in accordance with the guidelines of the Japanese Diabetes Society) significantly increased. Blood pressure and serum levels of triglycerides and total cholesterol decreased significantly. Furthermore, the Pittsburgh Sleep Quality Index (PSQI) and Diabetes Symptomatic Scores improved significantly. Adverse events such as hypoglycemia and loss of consciousness occurred in twenty three subjects (11%). Conclusions: These results suggest that the actions of DPP-4 inhibitors improve not only glycemic control, but also blood pressure, lipid profiles, and quality of life (QOL). Sitagliptin is a sound agent for use in the comprehensive treatment of patients with T2DM.Keywords
This publication has 30 references indexed in Scilit:
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisCardiovascular Diabetology, 2013
- Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)Cardiovascular Diabetology, 2012
- A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markersCardiovascular Diabetology, 2011
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Using the EQ-5D Index Score as a Predictor of Outcomes in Patients With Type 2 DiabetesMedical Care, 2009
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysisBMC Endocrine Disorders, 2008
- Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in MiceDiabetes, 2007
- The Dutch tariff: results and arguments for an effective design for national EQ‐5D valuation studiesHealth Economics, 2006
- GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in ratsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Impact of sleep debt on metabolic and endocrine functionThe Lancet, 1999